Day: August 26, 2021

Figure 1Plan view showing main target areas being tested during the Phase 1 diamond drilling program by Major Precious Metals at SkaergaardVANCOUVER, British Columbia, Aug. 26, 2021 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) (CSE:SIZE | OTC:SIZYF | FRANKFURT:3EZ) is pleased to provide an update on its Phase I diamond drilling program at its Skaergaard Project (“Skaergaard”) in eastern Greenland. Drilling commenced in July and has prioritized the northern part of the Skaergaard deposit including several areas being drilled to determine the open-cut potential at Skaergaard. Historically, these priority areas were never drilled at Skaergaard due to the focus being on defining a resource in the southern part of the deposit. Successful completion of these drill holes within...

HOUSTON, Aug. 25, 2021 (GLOBE NEWSWIRE) — Sharps Compliance Corp. (Nasdaq: SMED) (the “Company”) today announced the pricing of an underwritten public offering of 1,800,000 shares of its common stock at a public offering price of $8.65 per share. The Company has also granted to the underwriters a 30-day option to acquire an additional 270,000 shares to cover overallotments in connection with the offering. After the underwriting discount and before estimated offering expenses payable by the Company, the Company expects to receive net proceeds of approximately $14.8 million, assuming no exercise of the overallotment option. The offering is expected to close on August 30, 2021, subject to customary closing conditions. Roth Capital Partners is acting as sole manager for the offering. Sharps Compliance Corp. intends to use the net proceeds...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 25, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer (“TNBC”) or advanced endometrial cancer (“EC”) in the U.S. The first patient was dosed on August 24, 2021. This trial is to explore the potential for the addition of a highly selective vascular endothelial growth factor receptor (“VEGFR”) inhibitor, fruquintinib, to anti-programmed death-1 (“PD-1”) antibody tislelizumab in inducing activity to immune checkpoint inhibitors. This is an open-label, multi-center, non-randomized study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally...